I agree with you regarding the potential of ACV1. Fortunately,...

I agree with you regarding the potential of ACV1.

Fortunately, we should be very good indications of efficacy (or the lack thereof) by June or so.

Since my investment in this company is already in the tank, I can handle the additional minor loss involved if it goes to zero with a lot less pain than with the loss involved the move from $1 to 20 cents. So, I'm hanging on for the results of the sciatica trial.

If the results are positive, AND Metabolic partners up on the drug proptly on resonable terms, we could see a recovery in the share price in the fairly near term.

Looking back, I have to wonder if some sort of partnering deal could have been had on AOD9604 in the spring of 2005 or earlier. It's one thing to try to optimise retrun to investors by derisking a drug, but there is also a point to be made regarding spreading the risk out to a big player.

A mini-cap like Metabolic needs to be concerned about surviving failure and living to fight another day. Past strategy has succeeded only in putting the company - and the investors - into a very precarious position.